<DOC>
	<DOCNO>NCT01242748</DOCNO>
	<brief_summary>A phase III extension trial compare efficacy safety degarelix 3 month depot establish therapy Zoladex 3 month implant patient prostate cancer .</brief_summary>
	<brief_title>A Degarelix Trial Patients With Prostate Cancer</brief_title>
	<detailed_description>CS35A open-label , multicentre , comparative non-inferiority extension trial Phase 3 CS35 trial ( NCT00946920 ) . In main CS35 trial , participant randomise 2:1 treatment degarelix goserelin , respectively . All participant complete main CS35 trial initiation CS35A trial eligible enrol extension trial , provide treatment could continue uninterrupted . Patients enter CS35A trial continue 3-monthly treatment receive CS35 ( i.e . degarelix 480 mg goserelin 10.8 mg ) . It intend patient enrol CS35A trial would receive treatment degarelix goserelin 3-month interval period 40 month ( include 13 month ' treatment CS35 ) . It , however , decide prematurely terminate CS35A trial due insufficient number patient enrol . Maximum exposure treatment 111 week ( treatment arm ) . The baseline characteristic base CS35A Full Analysis Set ( FAS ) define participant receive least one dose degarelix goserelin acetate CS35A least one efficacy assessment dose . All efficacy analyse perform CS35/CS35A FAS define participant receive least one dose degarelix goserelin acetate CS35 least one efficacy assessment dose . All safety analysis perform CS35/CS35A Safety analysis set , include patient receive least one dose degarelix goserelin acetate CS35 .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<criteria>Has give write consent prior trialrelated activity perform . ( A trialrelated activity define procedure would perform normal management patient ) . Has complete CS35 trial . Has withdraw CS35 trial . Has end trial visit CS35 prior approval CS35A protocol .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>